Product Description
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Type 2 Diabetes|General Diabetes
Phase 2: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2011-001935-21 | P3 |
Completed |
General Diabetes |
2011-12-21 |
|
BC21625 | P3 |
Completed |
Type 2 Diabetes |
2011-03-01 |
|
BC21713 | P3 |
Completed |
Type 2 Diabetes |
2011-03-01 |
|
ND | P3 |
Terminated |
Type 2 Diabetes |
2011-01-31 |